A U.S. judge on Monday rejected Bristol Myers Squibb’s bid to dismiss a $6.7 billion lawsuit claiming it cheated shareholders of the former Celgene by delaying federal approval for three drugs, including the cancer treatment Breyanzi, by specified deadlines. While …
Depreciation on ACV is OK, Court Says in Knocking Down Class Action vs. Cincinnati
A property insurer is on solid ground in applying depreciation to actual cash value, as long as the policy makes that plan clear, a federal